Structure-based rational design enables efficient discovery of a new selective and potent AKT PROTAC degrader

被引:17
作者
Zhu, Cheng-Liang [2 ,4 ,7 ]
Luo, Xiaomin [1 ]
Tian, Tian [3 ]
Rao, Zijian [2 ]
Wang, Hanlin [10 ]
Zhou, Zhesheng [2 ]
Mi, Tian [5 ]
Chen, Danni [2 ]
Xu, Yongjin [9 ]
Wu, Yizhe
Che, Jinxin [3 ]
Zhou, Yubo [1 ,5 ,6 ]
Li, Jia [1 ,5 ,6 ]
Dong, Xiaowu [3 ,7 ,8 ]
机构
[1] Nanjing Univ Chinese Med, Sch Chinese Mat Med, Nanjing 210023, Peoples R China
[2] Zhejiang Univ, Inst Pharmacol & Toxicol, Coll Pharmaceut Sci, Zhejiang Prov Key Lab Anticanc Drug Res, Hangzhou 310058, Peoples R China
[3] Zhejiang Univ, Hangzhou Inst Innovat Med, Inst Drug Discovery & Design, Coll Pharmaceut Sci, Hangzhou 310058, Peoples R China
[4] Ctr Drug Safety Evaluat & Res ZJU, Hangzhou 310058, Peoples R China
[5] Chinese Acad Sci, Shanghai Inst Mat Med, Natl Ctr Drug Screening, State Key Lab Drug Res, Shanghai 201203, Peoples R China
[6] Chinese Acad Sci, Zhongshan Inst Drug Discovery, Shanghai Inst Mat Med, Zhongshan Tsuihang New Di 528400, Guangdon, Peoples R China
[7] Zhejiang Univ, Innovat Inst Artificial Intelligence Med, Hangzhou 310016, Peoples R China
[8] Zhejiang Univ, Canc Ctr, Hangzhou 310058, Peoples R China
[9] Canc Hosp Univ Chinese Acad Sci, Chinese Acad Sci, Zhejiang Canc Hosp, Inst Basic Med & Canc, Hangzhou 310005, Peoples R China
[10] Fudan Univ, Sch Pharm, Shanghai 200032, Peoples R China
基金
中国国家自然科学基金;
关键词
AKT; Protein kinase B; PROTAC; Chemical degrader; Rational design; MANTLE CELL LYMPHOMA; BIOLOGICAL EVALUATION; PATHWAY; DEGRADATION; INHIBITION; DERIVATIVES; BTK; IBRUTINIB; MK-2206; TARGET;
D O I
10.1016/j.ejmech.2022.114459
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
AKT and associated signaling pathways have been recognized as promising therapeutic targets for decades, and growing evidence indicates that inhibition or degradation of cellular AKT are viable strategies to treat cancer. Guided by an in silico modeling approach for rational linker design and based on our previous work in this field, we herein efficiently synthesized a small group of cereblon-recruiting AKT PROTAC molecules and identified a highly potent AKT degrader B4. Compared to the existing AKT degraders, B4 has a structurally unique AKT targeting warhead derived from the pyrazole-furan conjugated piperidine derivatives. It induces selective degradation of all three isoforms of AKT and exhibits efficacious anti-proliferation against several human hematological cancers. Notably, B4 demonstrates potent inhibition of AKT downstream signaling superior to its parental inhibitor. Together with its active analogs, B4 expands the arsenal of AKT chemical degraders as a valuable probe to uncover AKTs new functions and as a potential drug candidate to treat cancer.
引用
收藏
页数:15
相关论文
共 71 条
  • [1] Discovery of 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an Orally Bioavailable, Potent Inhibitor of Akt Kinases
    Addie, Matt
    Ballard, Peter
    Buttar, David
    Crafter, Claire
    Currie, Gordon
    Davies, Barry R.
    Debreczeni, Judit
    Dry, Hannah
    Dudley, Philippa
    Greenwood, Ryan
    Johnson, Paul D.
    Kettle, Jason G.
    Lane, Clare
    Lamont, Gillian
    Leach, Andrew
    Luke, Richard W. A.
    Morris, Jeff
    Ogilvie, Donald
    Page, Ken
    Pass, Martin
    Pearson, Stuart
    Ruston, Linette
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (05) : 2059 - 2073
  • [2] Perturbations of the AKT signaling pathway in human cancer
    Altomare, DA
    Testa, JR
    [J]. ONCOGENE, 2005, 24 (50) : 7455 - 7464
  • [3] Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta
    Bai, Nan
    Miller, Sven A.
    Andrianov, Grigorii, V
    Yates, Max
    Kirubakaran, Palani
    Karanicolas, John
    [J]. JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2021, 61 (03) : 1368 - 1382
  • [4] Unraveling the Role of Linker Design in Proteolysis Targeting Chimeras
    Bemis, Troy A.
    La Clair, James J.
    Burkart, Michael D.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (12) : 8042 - 8052
  • [5] Discovery and Preclinical Pharmacology of a Selective ATP-Competitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors
    Blake, James F.
    Xu, Rui
    Bencsik, Josef R.
    Xiao, Dengming
    Kallan, Nicholas C.
    Schlachter, Stephen
    Mitchell, Ian S.
    Spencer, Keith L.
    Banka, Anna L.
    Wallace, Eli M.
    Gloor, Susan L.
    Martinson, Matthew
    Woessner, Richard D.
    Vigers, Guy P. A.
    Brandhuber, Barbara J.
    Liang, Jun
    Safina, Brian S.
    Li, Jun
    Zhang, Birong
    Chabot, Christine
    Do, Steven
    Lee, Leslie
    Oeh, Jason
    Sampath, Deepak
    Lee, Brian B.
    Lin, Kui
    Liederer, Bianca M.
    Skelton, Nicholas J.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (18) : 8110 - 8127
  • [6] E3 Ligase Ligands in Successful PROTACs: An Overview of Syntheses and Linker Attachment Points
    Bricelj, Alesa
    Steinebach, Christian
    Kuchta, Robert
    Gutschow, Michael
    Sosic, Izidor
    [J]. FRONTIERS IN CHEMISTRY, 2021, 9
  • [7] Maximising the potential of MKT inhibitors as anti-cancer treatments
    Brown, Jessica S.
    Banerji, Udai
    [J]. PHARMACOLOGY & THERAPEUTICS, 2017, 172 : 101 - 115
  • [8] Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery
    Burslem, George M.
    Crews, Craig M.
    [J]. CELL, 2020, 181 (01) : 102 - 114
  • [9] Cerulli RA, 2014, BLOOD, V124
  • [10] Discovery of N-((3S,4S)-4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl-1H-pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity
    Che, Jinxin
    Dai, Xiaoyang
    Gao, Jian
    Sheng, Haichao
    Zhan, Wenhu
    Lu, Yang
    Li, Dan
    Gao, Zizheng
    Jin, Zegao
    Chen, Binhui
    Luo, Peihua
    Yang, Bo
    Hu, Yongzhou
    He, Qiaojun
    Weng, Qinjie
    Dong, Xiaowu
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (16) : 12163 - 12180